354 related articles for article (PubMed ID: 29718973)
21. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib.
Alkebsi L; Wang X; Ohkawara H; Fukatsu M; Mori H; Ikezoe T
Int J Hematol; 2021 Mar; 113(3):441-455. PubMed ID: 33392972
[TBL] [Abstract][Full Text] [Related]
23. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.
Vittal R; Horowitz JC; Moore BB; Zhang H; Martinez FJ; Toews GB; Standiford TJ; Thannickal VJ
Am J Pathol; 2005 Feb; 166(2):367-75. PubMed ID: 15681821
[TBL] [Abstract][Full Text] [Related]
24. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
26. Bosutinib.
Keller G; Schafhausen P; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
[TBL] [Abstract][Full Text] [Related]
27. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
28. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis.
Wei Y; Kim TJ; Peng DH; Duan D; Gibbons DL; Yamauchi M; Jackson JR; Le Saux CJ; Calhoun C; Peters J; Derynck R; Backes BJ; Chapman HA
J Clin Invest; 2017 Oct; 127(10):3675-3688. PubMed ID: 28872461
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis.
Koh RY; Lim CL; Uhal BD; Abdullah M; Vidyadaran S; Ho CC; Seow HF
Mol Med Rep; 2015 May; 11(5):3808-13. PubMed ID: 25585520
[TBL] [Abstract][Full Text] [Related]
31. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
32. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
33. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
34. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
35. Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.
Wermuth PJ; Carney KR; Mendoza FA; Piera-Velazquez S; Jimenez SA
Lab Invest; 2017 Jul; 97(7):806-818. PubMed ID: 28346399
[TBL] [Abstract][Full Text] [Related]
36. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Coluccia AM; Benati D; Dekhil H; De Filippo A; Lan C; Gambacorti-Passerini C
Cancer Res; 2006 Feb; 66(4):2279-86. PubMed ID: 16489032
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory effect of ginsan on TGF-β mediated fibrotic process.
Ahn JY; Kim MH; Lim MJ; Park S; Lee SL; Yun YS; Song JY
J Cell Physiol; 2011 May; 226(5):1241-7. PubMed ID: 20945375
[TBL] [Abstract][Full Text] [Related]
39. Prolidase-dependent regulation of TGF β (corrected) and TGF β receptor expressions in human skin fibroblasts.
Surazynski A; Miltyk W; Prokop I; Palka J
Eur J Pharmacol; 2010 Dec; 649(1-3):115-9. PubMed ID: 20868675
[TBL] [Abstract][Full Text] [Related]
40. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
